不同化疗方案联合沙利度胺治疗确诊的艾滋病相关弥漫大B细胞淋巴瘤的疗效和安全性

IF 0.7 Q4 HEMATOLOGY

Leukemia Research Reports Pub Date : 2024-01-01 DOI:10.1016/j.lrr.2024.100450

Peng fei Tao, Chuan Qian, Qi wen zhou, Sen Lin, Dan qing Wang, Xi Wang, Shi fen Chen, Hai yan Min

{"title":"不同化疗方案联合沙利度胺治疗确诊的艾滋病相关弥漫大B细胞淋巴瘤的疗效和安全性","authors":"Peng fei Tao, Chuan Qian, Qi wen zhou, Sen Lin, Dan qing Wang, Xi Wang, Shi fen Chen, Hai yan Min","doi":"10.1016/j.lrr.2024.100450","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the short-term efficacy and safety of different chemotherapy regimens combined with thalidomide, in the treatment of low-income patients with newly diagnosed HIV-associated diffuse large B-cell lymphoma.</p></div><div><h3>Methods</h3><p>A retrospective analysis was performed on 42 patients with HIV-DLBCL who were admitted to the Infectious Diseases Department of Yunnan Provincial Infectious Diseases Hospital from January 2018 to December 2020. 14 cases (including 1 case in stage II and 13 cases in stage III/IV) were treated with R-CHOP, 24 cases (including 1 case in stage II and 23 cases in stage III/IV) were treated with R-DAEPOCH, and 4 cases (including 1 case in stage II and 3 cases in stage III/IV) were treated with EPOCH. All patients were treated with thalidomide. The ART regimen was adjusted. At least 1 and up to 6 intrathecal injections were given during chemotherapy, and cotrimoxazole was taken orally to prevent infection. The clinical efficacy was evaluated after 4 cycles of chemotherapy, and adverse events were evaluated at each cycle of chemotherapy.</p></div><div><h3>Results</h3><p>All patients received 1–8 cycles of chemotherapy. CR (64.2 %) was achieved in 9 patients in R-CHOP group, and 5 patients died. In the R-DAEPOCH group, 17 patients achieved CR (70.8 %) and 7 died. In the EPOCH group, 2 patients reached CR (50 %) and 2 died. The main adverse reactions were grade II and above myelosuppression.</p></div><div><h3>Conclusion</h3><p>Combined treatment with thalidomide can improve the prognosis of low-income patients with newly diagnosed HIV-DLBCL.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100450"},"PeriodicalIF":0.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000402/pdfft?md5=939dd388c2eea78951775be803e597f5&pid=1-s2.0-S2213048924000402-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of different chemotherapy regimens combined with thalidomide in the treatment of diagnosed HIV-associated diffuse large B-cell lymphoma\",\"authors\":\"Peng fei Tao, Chuan Qian, Qi wen zhou, Sen Lin, Dan qing Wang, Xi Wang, Shi fen Chen, Hai yan Min\",\"doi\":\"10.1016/j.lrr.2024.100450\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>To investigate the short-term efficacy and safety of different chemotherapy regimens combined with thalidomide, in the treatment of low-income patients with newly diagnosed HIV-associated diffuse large B-cell lymphoma.</p></div><div><h3>Methods</h3><p>A retrospective analysis was performed on 42 patients with HIV-DLBCL who were admitted to the Infectious Diseases Department of Yunnan Provincial Infectious Diseases Hospital from January 2018 to December 2020. 14 cases (including 1 case in stage II and 13 cases in stage III/IV) were treated with R-CHOP, 24 cases (including 1 case in stage II and 23 cases in stage III/IV) were treated with R-DAEPOCH, and 4 cases (including 1 case in stage II and 3 cases in stage III/IV) were treated with EPOCH. All patients were treated with thalidomide. The ART regimen was adjusted. At least 1 and up to 6 intrathecal injections were given during chemotherapy, and cotrimoxazole was taken orally to prevent infection. The clinical efficacy was evaluated after 4 cycles of chemotherapy, and adverse events were evaluated at each cycle of chemotherapy.</p></div><div><h3>Results</h3><p>All patients received 1–8 cycles of chemotherapy. CR (64.2 %) was achieved in 9 patients in R-CHOP group, and 5 patients died. In the R-DAEPOCH group, 17 patients achieved CR (70.8 %) and 7 died. In the EPOCH group, 2 patients reached CR (50 %) and 2 died. The main adverse reactions were grade II and above myelosuppression.</p></div><div><h3>Conclusion</h3><p>Combined treatment with thalidomide can improve the prognosis of low-income patients with newly diagnosed HIV-DLBCL.</p></div>\",\"PeriodicalId\":38435,\"journal\":{\"name\":\"Leukemia Research Reports\",\"volume\":\"21 \",\"pages\":\"Article 100450\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2213048924000402/pdfft?md5=939dd388c2eea78951775be803e597f5&pid=1-s2.0-S2213048924000402-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213048924000402\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213048924000402","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

摘要】目的探讨不同化疗方案联合沙利度胺治疗低收入新诊断HIV相关弥漫大B细胞淋巴瘤患者的短期疗效和安全性。方法对2018年1月至2020年12月云南省传染病医院感染科收治的42例HIV-DLBCL患者进行回顾性分析。14例（其中Ⅱ期1例，Ⅲ/Ⅳ期13例）采用R-CHOP治疗，24例（其中Ⅱ期1例，Ⅲ/Ⅳ期23例）采用R-DAEPOCH治疗，4例（其中Ⅱ期1例，Ⅲ/Ⅳ期3例）采用EPOCH治疗。所有患者均接受了沙利度胺治疗。抗逆转录病毒疗法进行了调整。化疗期间进行了至少1次、最多6次鞘内注射，并口服复方新诺明以预防感染。化疗4个周期后评估临床疗效，每个化疗周期评估不良反应。R-CHOP组9名患者达到CR（64.2%），5名患者死亡。在R-DAEPOCH组中，17名患者达到CR（70.8%），7名患者死亡。在 EPOCH 组中，2 名患者达到 CR（50%），2 名患者死亡。结论与沙利度胺联合治疗可改善新诊断为HIV-DLBCL的低收入患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy and safety of different chemotherapy regimens combined with thalidomide in the treatment of diagnosed HIV-associated diffuse large B-cell lymphoma

Objective

To investigate the short-term efficacy and safety of different chemotherapy regimens combined with thalidomide, in the treatment of low-income patients with newly diagnosed HIV-associated diffuse large B-cell lymphoma.

Methods

A retrospective analysis was performed on 42 patients with HIV-DLBCL who were admitted to the Infectious Diseases Department of Yunnan Provincial Infectious Diseases Hospital from January 2018 to December 2020. 14 cases (including 1 case in stage II and 13 cases in stage III/IV) were treated with R-CHOP, 24 cases (including 1 case in stage II and 23 cases in stage III/IV) were treated with R-DAEPOCH, and 4 cases (including 1 case in stage II and 3 cases in stage III/IV) were treated with EPOCH. All patients were treated with thalidomide. The ART regimen was adjusted. At least 1 and up to 6 intrathecal injections were given during chemotherapy, and cotrimoxazole was taken orally to prevent infection. The clinical efficacy was evaluated after 4 cycles of chemotherapy, and adverse events were evaluated at each cycle of chemotherapy.

Results

All patients received 1–8 cycles of chemotherapy. CR (64.2 %) was achieved in 9 patients in R-CHOP group, and 5 patients died. In the R-DAEPOCH group, 17 patients achieved CR (70.8 %) and 7 died. In the EPOCH group, 2 patients reached CR (50 %) and 2 died. The main adverse reactions were grade II and above myelosuppression.